From: DNA methylation predicts the outcome of COVID-19 patients with acute respiratory distress syndrome
Variable | COVID-19, died N = 24a | COVID-19, survived N = 76a | p-valub |
---|---|---|---|
Age | 58 (52, 63) | 47 (41, 56) | < 0.001 |
Gender (male) | 24 (100%) | 70 (92%) | 0.023 |
BMI (kg/m2) | 25.7 (24.5, 29.7) | 27.5 (25.4, 32.1) | 0.072 |
Ethnicity | |||
Middle East | 1 (4.1%) | 2 (2.6%) | 0.14 |
North Africa | 0 (0%) | 1 (1.3%) | |
Northeast Africa | 2 (8.2%) | 4 (5.2%) | |
South Asia | 18 (75%) | 63 (82.8%) | |
Southeast Asia | 2 (8.2%) | 5 (6.5%) | |
Western Asia | 1 (4.1%) | 1 (1.3%) | |
Duration of MV (days) | 25 (19, 41) | 8 (5, 18) | < 0.001 |
ICU LoS (days) | 26 (20, 48) | 15 (11, 29) | < 0.001 |
ECMO | 7 (29%) | 10 (13%) | 0.001 |
Nosocomial infections | 22 (92%) | 42 (55.2%) | < 0.001 |
Convalescent plasma therapy | 9 (37.5%) | 25 (32.8%) | 0.4 |
Diabetes status | |||
No diabetes | 15 (62.5%) | 41 (53.9%) | 0.14 |
Pre-diabetes | 1 (4.1%) | 4 (5.2%) | |
Diabetes | 8 (33.4%) | 31 (40.7%) | |
Hypertension | 11 (46%) | 31 (40.7%) | 0.5 |
Coronary artery disease | 1 (4.1%) | 4 (6.2%) | 0.8 |
Chronic kidney failure | 3 (12.5%) | 8 (10.5%) | 0.3 |
Chronic heart failure | 1 (4.1%) | 3 (3.9%) | 0.9 |